Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 May;2(2):159-66.
doi: 10.4103/0974-777X.62886.

Liposomal amphotericin B and leishmaniasis: dose and response

Shyam Sundar  1 , Jaya Chakravarty
Affiliations

Liposomal amphotericin B and leishmaniasis: dose and response

Shyam Sundar et al. J Glob Infect Dis. 2010 May.

Abstract

Liposomal amphotericin B has been used with increasing frequency to treat visceral leishmaniasis (VL). It is the treatment of choice for immunocompetent patients in the Mediterranean region and the preferred drug for HIV/VL co-infection. Although there is a regional variation in the susceptibility of the parasite a total dose of 20 mg/kg is effective in immunocompetent patients. Randomized clinical trials of liposomal amphotericin B in the treatment and secondary prophylaxis of HIV-VL coinfected patients is urgently needed to optimize treatment in this subset. With the availability of Liposomal amphotericin B at a preferential pricing in the endemic areas, short course combination therapy can become a viable alternative.

Keywords: Amphotericin B; Kala-azar; Liposomal.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

References

    1. World Health Organization. Leishmaniasis disease burden. Available from: http://www.who.int/leishmaniasis/burden/en/. Accessed on 2.9.2009.
    1. Pearson RD, Jeronimo SMB, de Queiroz Sousa A. Leishmaniasis. In: Guerrant RL, Walker DH, Weller PF, editors. Tropical infectious diseases: principles, pathogens and practice. Philadelphia: Churchill Livingstone; 1999. pp. 797–813.
    1. Bern C, Hightower AW, Chowdhury R, Ali M, Amann J, Wagatsuma Y, et al. Risk factors for kala-azar in Bangladesh. Emerg Infect Dis. 2005;11:655–62. - PMC - PubMed
    1. Addy M, Nandy A. Ten years of kala-azar in west Bengal, part I: did post-kala-azar dermal leishmaniasis initiate the outbreak in 24-Parganas? Bull World Health Organ. 1992;70:341–6. - PMC - PubMed
    1. Minutes of the Meeting of the Expert Committee for the Treatment of Kala-azar in India. 2000